- Home
- IQI vs PCRX Comparison
IQI vs PCRX Comparison
Compare IQI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IQI | PCRX |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.5M | 1.0B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | IQI | PCRX |
|---|---|---|
| Price | $9.88 | $26.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.86 |
| AVG Volume (30 Days) | 162.1K | ★ 870.0K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | N/A | $9.53 |
| P/E Ratio | ★ N/A | $55.18 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $8.05 | $18.17 |
| 52 Week High | $10.00 | $27.64 |
Technical Indicators
Market Signals| Indicator | IQI | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.29 | 63.56 |
| Support Level | $9.93 | $25.56 |
| Resistance Level | $10.00 | $27.16 |
| Average True Range (ATR) | 0.06 | 1.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 5.36 | 81.01 |
Price Performance
Historical ComparisonAbout IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.